Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Shivalik Rasayan Limited

Market Cap 3.49B 36.94M 31.84M 29.32M 27.53M 51.68M 52.22M 346M 135M 1.71B 139M 136M 5.93B P/E Ratio 2024
69.1x
P/E Ratio 2025 59.1x
Enterprise Value 4.26B 45.06M 38.83M 35.76M 33.57M 63.04M 63.7M 423M 165M 2.09B 169M 166M 7.23B EV / Sales 2024
3.49x
EV / Sales 2025 3.4x
Free-Float
40.79%
Yield 2024
0.09%
Yield 2025 0.08%
05-27 Shivalik Rasayan Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-27 Shivalik Rasayan Limited Announces Resignation of Sanjay Bansal as Non-Executive Director, Effective May 27, 2026 CI
05-27 Shivalik Rasayan Limited Recommends Final Dividend for the Financial Year 2025-26 CI
05-27 Shivalik Rasayan Ltd March-quarter consol net profit 45.3 million rupees RE
02-13 Shivalik Rasayan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Shivalik Rasayan Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
29/09/25 Shivalik Rasayan Limited Approves the Re-Designation of Mr. Ashwani Kumar Sharma as a Non-Executive, Non-Independent Director CI
12/08/25 Shivalik Rasayan Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Shivalik Rasayan Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
30/05/25 Shivalik Rasayan Limited announces Annual dividend, payable on October 27, 2025 CI
24/04/25 Medicamen Biotech Limited announced that it has received INR 535.6816 million in funding from Kim Ginnerup ApS, Shivalik Rasayan Limited, VERALOGIX HOLDINGS LTD and other investors CI
26/02/25 Medicamen Biotech Limited announced that it expects to receive INR 775.7875 million in funding from Kim Ginnerup ApS, Shivalik Rasayan Limited, VERALOGIX HOLDINGS LTD CI
04/10/24 Shivalik Rasayan Gets US FDA Nod for Pharmaceutical Ingredient Facility in Gujarat; Shares Rise 3% MT
1 day+3.48%
1 week-3.99%
Current month-22.09%
1 month-11.95%
3 months-12.71%
6 months-39.76%
Current year-36.03%
1 week 214.1
Extreme 214.1
245
1 month 214.1
Extreme 214.1
303
Current year 207.7
Extreme 207.7
371.3
1 year 207.7
Extreme 207.7
652.75
3 years 207.7
Extreme 207.7
890.05
5 years 207.7
Extreme 207.7
1,196.8
10 years 34
Extreme 34
1,196.8
Manager TitleAgeSince
Chief Executive Officer 64 17/11/2018
Director of Finance/CFO - 01/11/2001
Chief Tech/Sci/R&D Officer - 11/01/2024
Director TitleAgeSince
Chairman 61 23/02/2002
Director/Board Member 66 18/07/2003
Director/Board Member - 13/11/2018
Date Insider Type Main position Quantity % Market Cap.
01/07/24Don 21,500 0.1382%
26/06/24Sell 108,500 0.6973%
Change 5-day change 1-year change 3-year change Capi.($)
+3.48%-3.99%-58.43%-69.71% 36.66M
+1.70%+2.61%+3.74%+34.48% 50.64B
+0.11%-.--%-.--%-.--% 12.96B
-1.54%-2.05%+99.07%+176.15% 12.15B
-1.92%+5.84%+34.12%+78.13% 8.41B
-5.48%-2.77%-18.27%-8.66% 7.42B
+10.13%+15.17%-1.73%+156.34% 6.2B
-0.21%-1.53%-2.70%-9.59% 5.51B
+1.70%+7.48%-27.49%-25.27% 4.55B
+0.12%+5.83%+1.38%+1.17% 3.68B
Average +0.81%+2.53%+2.97%+33.30% 11.16B
Weighted average by Cap. +0.74%+1.87%+12.52%+47.36%

Financials

2024 2025
Net sales 2.72B 28.72M 24.75M 22.79M 21.4M 40.18M 40.6M 269M 105M 1.33B 108M 105M 4.61B 3.1B 32.74M 28.22M 25.98M 24.4M 45.8M 46.29M 307M 120M 1.52B 123M 120M 5.25B
Net income 127M 1.35M 1.16M 1.07M 1M 1.88M 1.9M 12.61M 4.91M 62.28M 5.05M 4.94M 216M 167M 1.77M 1.52M 1.4M 1.32M 2.47M 2.5M 16.56M 6.45M 81.76M 6.63M 6.49M 283M
Net Debt 482M 5.1M 4.4M 4.05M 3.8M 7.14M 7.21M 47.84M 18.64M 236M 19.14M 18.74M 818M 768M 8.12M 7M 6.44M 6.05M 11.36M 11.48M 76.13M 29.66M 376M 30.47M 29.82M 1.3B
Logo Shivalik Rasayan Limited
Shivalik Rasayan Limited is an India-based company. The Company’s segments are engaged in agrochemicals, active pharma ingredients (API), and pharma formulation. It is the producer of Malathion Technical and Dimethoate Technical. Malathion Technical is a non-systemic, wide spectrum organophosphorus (OP) based contact insecticide. Dimethoate Technical is used in preparation of formulations used in the control of a range of insects and mites. It also manufactures organophosphorus-based insecticides and chemicals. It has a diverse product range and product mix in order to serve consumer requirements. The APIs are being developed and manufactured in the niche area of oncology, ARVs, cardiovascular, metabolic disorders and immunology. It offers solutions from product selection to development to commercialization for a range of oncology and non-oncology products. The Company’s oncology products include Azacitidine, Busulfan, Bortezomib, and various others.
Employees
275
Date Price Change Volume
16/06/26 227.65 +3.48% 3,957
15/06/26 220.00 -2.31% 15,453
12/06/26 225.20 -3.24% 4,021
11/06/26 232.75 -5.00% 286
10/06/26 245.00 +3.22% 1,146
  1. Stock Market
  2. Stocks
  3. SHIVALIK Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!